Intech Investment Management LLC Takes $765,000 Position in IQVIA Holdings Inc. $IQV

Intech Investment Management LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,030 shares of the medical research company’s stock, valued at approximately $765,000.

Other hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its stake in shares of IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares during the period. CVA Family Office LLC grew its position in shares of IQVIA by 11.6% in the third quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 68 shares during the period. UMB Bank n.a. increased its stake in IQVIA by 11.0% in the third quarter. UMB Bank n.a. now owns 749 shares of the medical research company’s stock valued at $142,000 after purchasing an additional 74 shares during the last quarter. E Fund Management Co. Ltd. lifted its position in IQVIA by 3.7% during the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after buying an additional 74 shares during the period. Finally, Hartford Investment Management Co. boosted its stake in IQVIA by 0.8% in the 3rd quarter. Hartford Investment Management Co. now owns 9,964 shares of the medical research company’s stock worth $1,893,000 after buying an additional 77 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $174.00 to $213.00 in a research note on Monday. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Truist Financial dropped their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Finally, Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $229.13.

IQVIA Stock Performance

NYSE:IQV opened at $178.87 on Tuesday. The firm’s fifty day simple moving average is $206.26 and its 200 day simple moving average is $207.53. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The firm has a market capitalization of $30.35 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 1.68 and a beta of 1.40.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.